Scott Friedman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7745068/publications.pdf

Version: 2024-02-01

461 papers	66,585 citations	764 119 h-index	813 246 g-index
488 all docs	488 docs citations	488 times ranked	57031 citing authors

#	Article	IF	Citations
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	4.3	4,701
2	Mechanisms of NAFLD development and therapeutic strategies. Nature Medicine, 2018, 24, 908-922.	15.2	2,392
3	Mechanisms of Hepatic Fibrogenesis. Gastroenterology, 2008, 134, 1655-1669.	0.6	2,381
4	Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver. Physiological Reviews, 2008, 88, 125-172.	13.1	2,345
5	Molecular Regulation of Hepatic Fibrosis, an Integrated Cellular Response to Tissue Injury. Journal of Biological Chemistry, 2000, 275, 2247-2250.	1.6	1,855
6	Mechanisms of hepatic stellate cell activation. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 397-411.	8.2	1,821
7	Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology, 2015, 149, 367-378.e5.	0.6	1,592
8	Liver fibrosis â€“ from bench to bedside. Journal of Hepatology, 2003, 38, 38-53.	1.8	1,437
9	Pathogenesis of Liver Fibrosis. Annual Review of Pathology: Mechanisms of Disease, 2011, 6, 425-456.	9.6	1,382
10	The Cellular Basis of Hepatic Fibrosis -- Mechanisms and Treatment Strategies. New England Journal of Medicine, 1993, 328, 1828-1835.	13.9	1,377
11	Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma. New England Journal of Medicine, 2008, 359, 1995-2004.	13.9	1,148
12	Integrative Transcriptome Analysis Reveals Common Molecular Subclasses of Human Hepatocellular Carcinoma. Cancer Research, 2009, 69, 7385-7392.	0.4	978
13	Hepatic stellate cells as key target in liver fibrosis. Advanced Drug Delivery Reviews, 2017, 121, 27-42.	6.6	943
14	Liver Cancer Cell of Origin, Molecular Class, and Effects onÂPatient Prognosis. Gastroenterology, 2017, 152, 745-761.	0.6	838
15	p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs. Journal of Experimental Medicine, 1998, 188, 2033-2045.	4.2	788
16	Mechanisms of hepatic fibrogenesis. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2011, 25, 195-206.	1.0	772
17	Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell, 2021, 184, 2537-2564.	13.5	757
18	Pathobiology of liver fibrosis: a translational success story. Gut, 2015, 64, 830-841.	6.1	739

#	Article	IF	Citations
19	Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. Gastroenterology, 2017, 153, 812-826.	0.6	650
20	Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma. Gastroenterology, 2008, 135, 1972-1983.e11.	0.6	644
21	Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology, 2007, 45, 938-947.	3.6	632
22	Role of the Microenvironment in the Pathogenesis and Treatment of Hepatocellular Carcinoma. Gastroenterology, 2013, 144, 512-527.	0.6	600
23	Focal Gains of VEGFA and Molecular Classification of Hepatocellular Carcinoma. Cancer Research, 2008, 68, 6779-6788.	0.4	589
24	Hepatic Stellate Cells and Liver Fibrosis. , 2013, 3, 1473-1492.		561
25	Hepatic fibrosis: Concept to treatment. Journal of Hepatology, 2015, 62, S15-S24.	1.8	554
26	Therapy for Fibrotic Diseases: Nearing the Starting Line. Science Translational Medicine, 2013, 5, 167sr1.	5.8	546
27	A randomized, placeboâ€controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology, 2018, 67, 1754-1767.	3.6	528
28	Autophagy Releases Lipid That Promotes Fibrogenesis by Activated Hepatic Stellate Cells in Mice and in Human Tissues. Gastroenterology, 2012, 142, 938-946.	0.6	523
29	Evolving challenges in hepatic fibrosis. Nature Reviews Gastroenterology and Hepatology, 2010, 7, 425-436.	8.2	516
30	Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. Journal of Hepatology, 2018, 68, 526-549.	1.8	506
31	Genomics and Signaling Pathways in Hepatocellular Carcinoma. Seminars in Liver Disease, 2007, 27, 055-076.	1.8	491
32	Apoptosis: The nexus of liver injury and fibrosis. Hepatology, 2004, 39, 273-278.	3.6	483
33	Senolytic CAR T cells reverse senescence-associated pathologies. Nature, 2020, 583, 127-132.	13.7	483
34	Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis. Hepatology, 2010, 51, 1445-1449.	3.6	436
35	Mechanisms of Disease: mechanisms of hepatic fibrosis and therapeutic implications. Nature Reviews Gastroenterology & Hepatology, 2004, 1, 98-105.	1.7	421
36	KLF6, a Candidate Tumor Suppressor Gene Mutated in Prostate Cancer. Science, 2001, 294, 2563-2566.	6.0	408

#	Article	IF	Citations
37	Functions of autophagy in normal and diseased liver. Autophagy, 2013, 9, 1131-1158.	4.3	384
38	A Molecular Signature to Discriminate Dysplastic Nodules From Early Hepatocellular Carcinoma in HCV Cirrhosis. Gastroenterology, 2006, 131, 1758-1767.	0.6	379
39	Apoptotic Body Engulfment by a Human Stellate Cell Line Is Profibrogenic. Laboratory Investigation, 2003, 83, 655-663.	1.7	370
40	Isolation and culture of hepatic lipocytes, Kupffer cells, and sinusoidal endothelial cells by density gradient centrifugation with Stractan. Analytical Biochemistry, 1987, 161, 207-218.	1.1	348
41	Reversal of hepatic fibrosis â€" Fact or fantasy?. Hepatology, 2006, 43, S82-S88.	3.6	348
42	Leptin in hepatic fibrosis: Evidence for increased collagen production in stellate cells and lean littermates ofob/obmice. Hepatology, 2002, 35, 762-771.	3.6	342
43	Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology, 2012, 56, 769-775.	3.6	338
44	A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. Journal of Hepatology, 2018, 69, 385-395.	1.8	330
45	Cytokines and Fibrogenesis. Seminars in Liver Disease, 1999, 19, 129-140.	1.8	319
46	Liver fibrogenesis and the role of hepatic stellate cells: New insights and prospects for therapy. Journal of Gastroenterology and Hepatology (Australia), 1999, 14, 618-633.	1.4	309
47	Hepatic fibrosisâ€"Overview. Toxicology, 2008, 254, 120-129.	2.0	301
48	Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseasesâ€“U.S. Food and Drug Administration Joint Workshop. Hepatology, 2015, 61, 1392-1405.	3.6	288
49	A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology, 2007, 46, 297-306.	3.6	285
50	Isolated hepatic lipocytes and kupffer cells from normal human liver: Morphological and functional characteristics in primary culture. Hepatology, 1992, 15, 234-243.	3.6	264
51	Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis. PLoS ONE, 2016, 11, e0158156.	1.1	258
52	Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosisin vivo. Hepatology, 2006, 43, 435-443.	3.6	257
53	Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib. Clinical Cancer Research, 2012, 18, 4997-5007.	3.2	251
54	An immortalized rat liver stellate cell line (HSC-T6): a new cell model for the study of retinoid metabolism in vitro. Journal of Lipid Research, 2000, 41, 882-893.	2.0	250

#	Article	IF	Citations
55	Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. Journal of Hepatology, 2006, 45, 60-71.	1.8	242
56	Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. Gastroenterology, 2004, 127, 870-882.	0.6	239
57	Molecular regulation of hepatic fibrogenesis. Journal of Hepatology, 1998, 29, 836-847.	1.8	238
58	Antiangiogenic treatment with Sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology, 2007, 46, 1919-1926.	3.6	236
59	Transcriptional Activation of Transforming Growth Factor Î²1 and Its Receptors by the Kruppel-like Factor Zf9/Core Promoter-binding Protein and Sp1. Journal of Biological Chemistry, 1998, 273, 33750-33758.	1.6	235
60	DDR2 receptor promotes MMP-2â€“mediated proliferation and invasion by hepatic stellate cells. Journal of Clinical Investigation, 2001, 108, 1369-1378.	3.9	235
61	Zf9, a Kruppel-like transcription factor up-regulatedin vivoduring early hepatic fibrosis. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 9500-9505.	3.3	234
62	Stimulation and proliferation of primary rat hepatic stellate cells by cytochrome P450 2E1-derived reactive oxygen species. Hepatology, 2002, 35, 62-73.	3.6	234
63	Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis. Fibrogenesis and Tissue Repair, 2010, 3, 21.	3.4	232
64	Expression and role of Bcl-xL in human hepatocellular carcinomas. Hepatology, 2001, 34, 55-61.	3.6	216
65	Hepatic fibrosis. Current Opinion in Gastroenterology, 2009, 25, 223-229.	1.0	212
66	Adenosine A2A receptors play a role in the pathogenesis of hepatic cirrhosis. British Journal of Pharmacology, 2006, 148, 1144-1155.	2.7	209
67	Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. Journal of Hepatology, 2009, 51, 725-733.	1.8	206
68	Discoidin Domain Receptor 2 Regulates Fibroblast Proliferation and Migration through the Extracellular Matrix in Association with Transcriptional Activation of Matrix Metalloproteinase-2. Journal of Biological Chemistry, 2002, 277, 3606-3613.	1.6	205
69	MicroRNA-Based Classification of Hepatocellular Carcinoma and Oncogenic Role of miR-517a. Gastroenterology, 2011, 140, 1618-1628.e16.	0.6	205
70	Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology, 2003, 37, 87-95.	3.6	204
71	Experimental models of hepatocellular carcinoma. Journal of Hepatology, 2008, 48, 858-879.	1.8	203
72	Endoplasmic reticulum stress induces fibrogenic activity in hepatic stellate cells through autophagy. Journal of Hepatology, 2013, 59, 98-104.	1.8	203

#	Article	IF	Citations
73	A Germline DNA Polymorphism Enhances Alternative Splicing of the KLF6 Tumor Suppressor Gene and Is Associated with Increased Prostate Cancer Risk. Cancer Research, 2005, 65, 1213-1222.	0.4	202
74	Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of toll-like receptor 4 to hepatic stellate cell responses. Hepatology, 2009, 49, 960-968.	3.6	201
75	Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis. Hepatology, 2013, 57, 1394-1406.	3.6	197
76	Prognostic Gene Expression Signature for Patients With Hepatitis Câ€“Related Early-Stage Cirrhosis. Gastroenterology, 2013, 144, 1024-1030.	0.6	195
77	Cellular Sources of Collagen and Regulation of Collagen Production in Liver. Seminars in Liver Disease, 1990, 10, 20-29.	1.8	194
78	Innate immunity in alcoholic liver disease. American Journal of Physiology - Renal Physiology, 2011, 300, G516-G525.	1.6	191
79	Fibrogenesis I. New insights into hepatic stellate cell activation: the simple becomes complex. American Journal of Physiology - Renal Physiology, 2000, 279, G7-G11.	1.6	181
80	Combination therapy for hepatocellular carcinoma: Additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. Journal of Hepatology, 2012, 56, 1343-1350.	1.8	181
81	Inhibition of rat hepatic lipocyte activation in culture by interferon-Î³. Hepatology, 1992, 16, 776-784.	3.6	180
82	Scraping fibrosis: Expressway to the core of fibrosis. Nature Medicine, 2011, 17, 552-553.	15.2	180
83	Regression of Fibrosis and Reversal of Cirrhosis in Rats by Galectin Inhibitors in Thioacetamide-Induced Liver Disease. PLoS ONE, 2013, 8, e75361.	1.1	180
84	Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design. Contemporary Clinical Trials, 2016, 47, 356-365.	0.8	178
85	The Kruppel-Like Factor 6 Genotype Is Associated With Fibrosis in Nonalcoholic Fatty Liver Disease. Gastroenterology, 2008, 135, 282-291.e1.	0.6	177
86	Cytochrome P450 2E1-derived Reactive Oxygen Species Mediate Paracrine Stimulation of Collagen I Protein Synthesis by Hepatic Stellate Cells. Journal of Biological Chemistry, 2002, 277, 9853-9864.	1.6	176
87	CYP2E1-mediated oxidative stress induces collagen type I expression in rat hepatic stellate cells. Hepatology, 1999, 30, 987-996.	3.6	175
88	Impaired endothelial autophagy promotes liver fibrosis by aggravating the oxidative stress response during acute liver injury. Journal of Hepatology, 2019, 70, 458-469.	1.8	173
89	The Power of Plasticityâ€"Metabolic Regulation of Hepatic Stellate Cells. Cell Metabolism, 2021, 33, 242-257.	7.2	173
90	HEPATIC FIBROSIS. Clinics in Liver Disease, 2001, 5, 315-334.	1.0	172

#	Article	IF	Citations
91	Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition. Cancer Cell, 2016, 30, 879-890.	7.7	172
92	Proangiogenic role of tumor-activated hepatic stellate cells in experimental melanoma metastasis. Hepatology, 2003, 37, 674-685.	3.6	171
93	Current status of novel antifibrotic therapies in patients with chronic liver disease. Therapeutic Advances in Gastroenterology, 2011, 4, 391-417.	1.4	171
94	Future Research Directions in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2002, 166, 236-246.	2.5	170
95	Transcriptional activation of endoglin and transforming growth factor-Î² signaling components by cooperative interaction between Sp1 and KLF6: their potential role in the response to vascular injury. Blood, 2002, 100, 4001-4010.	0.6	169
96	Hepatic fibrosis 2022: Unmet needs and a blueprint for the future. Hepatology, 2022, 75, 473-488.	3.6	169
97	Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancerâ˜†. Gastroenterology, 2004, 126, 1090-1103.	0.6	165
98	PAK proteins and YAP-1 signalling downstream of integrin beta-1 in myofibroblasts promote liver fibrosis. Nature Communications, 2016, 7, 12502.	5.8	162
99	KrÃ¼ppel-like Factor-6 Promotes Preadipocyte Differentiation through Histone Deacetylase 3-dependent Repression of DLK1. Journal of Biological Chemistry, 2005, 280, 26941-26952.	1.6	153
100	Cyclin-Dependent Kinase Inhibition by the KLF6 Tumor Suppressor Protein through Interaction with Cyclin D1. Cancer Research, 2004, 64, 3885-3891.	0.4	152
101	Is Liver Fibrosis Reversible?. New England Journal of Medicine, 2001, 344, 452-454.	13.9	151
102	Targeted Inhibition of the KLF6 Splice Variant, KLF6 SV1, Suppresses Prostate Cancer Cell Growth and Spread. Cancer Research, 2005, 65, 5761-5768.	0.4	151
103	Regression of Fibrosis after Chronic Stimulation of Cannabinoid CB2 Receptor in Cirrhotic Rats. Journal of Pharmacology and Experimental Therapeutics, 2008, 324, 475-483.	1.3	150
104	The Role of Chemokines in Acute Liver Injury. Frontiers in Physiology, 2012, 3, 213.	1.3	150
105	Antifibrotic Effects of CXCL9 and Its Receptor CXCR3 in Livers of Mice and Humans. Gastroenterology, 2009, 137, 309-319.e3.	0.6	149
106	Inhibition of PDGF, TGF-Î², and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib. Journal of Hepatology, 2011, 55, 612-625.	1.8	148
107	Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology, 2004, 40, 1047-1052.	3.6	142
108	Î²-PDGF receptor expressed by hepatic stellate cells regulates fibrosis in murine liver injury, but not carcinogenesis. Journal of Hepatology, 2015, 63, 141-147.	1.8	142

#	Article	IF	Citations
109	Gene-expression signature of vascular invasion in hepatocellular carcinoma. Journal of Hepatology, 2011, 55, 1325-1331.	1.8	133
110	Detection of novel biomarkers of liver cirrhosis by proteomic analysis. Hepatology, 2009, 49, 1257-1266.	3.6	132
111	Activation of hepatic stellate cells after phagocytosis of lymphocytes: A novel pathway of fibrogenesis. Hepatology, 2008, 48, 963-977.	3.6	131
112	Acute liver failure is associated with elevated liver stiffness and hepatic stellate cell activation. Hepatology, 2010, 52, 1008-1016.	3.6	131
113	Transplantation Trends in Primary Biliary Cirrhosis. Clinical Gastroenterology and Hepatology, 2007, 5, 1313-1315.	2.4	130
114	Adenovirus-mediated expression of BMP-7 suppresses the development of liver fibrosis in rats. Gut, 2007, 56, 706-714.	6.1	129
115	Retinoids in Cancer Chemoprevention. Current Cancer Drug Targets, 2004, 4, 285-298.	0.8	127
116	Developmental regulation of yolk sac hematopoiesis by Krul̂ppel-like factor 6. Blood, 2006, 107, 1357-1365.	0.6	126
117	Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. Hepatology, 2018, 67, 2001-2012.	3.6	125
118	Molecular mechanisms of hepatic fibrosis and principles of therapy. Journal of Gastroenterology, 1997, 32, 424-430.	2.3	123
119	Connective tissue biology and hepatic fibrosis: Report of a conference. Hepatology, 1990, 11, 488-498.	3.6	119
120	Dendritic cell regulation of carbon tetrachloride-induced murine liver fibrosis regression. Hepatology, 2012, 55, 244-255.	3.6	119
121	Discoidin Domain Receptor 2 Interacts with Src and Shc following Its Activation by Type I Collagen. Journal of Biological Chemistry, 2002, 277, 19206-19212.	1.6	118
122	A novel murine model to deplete hepatic stellate cells uncovers their role in amplifying liver damage in mice. Hepatology, 2013, 57, 339-350.	3.6	118
123	NRBF2 regulates autophagy and prevents liver injury by modulating Atg14L-linked phosphatidylinositol-3 kinase III activity. Nature Communications, 2014, 5, 3920.	5.8	117
124	Reversal, maintenance or progression: What happens to the liver after a virologic cure of hepatitis C?. Antiviral Research, 2014, 107, 23-30.	1.9	115
125	Identification of Two Gene Variants Associated With Risk of Advanced Fibrosis in Patients With Chronic Hepatitis C. Gastroenterology, 2006, 130, 1679-1687.	0.6	113
126	Ethanol and Arachidonic Acid Increase Î±2(I) Collagen Expression in Rat Hepatic Stellate Cells Overexpressing Cytochrome P450 2E1. Journal of Biological Chemistry, 2000, 275, 20136-20145.	1.6	112

#	Article	IF	Citations
127	Autophagy is a gatekeeper of hepatic differentiation and carcinogenesis by controlling the degradation of Yap. Nature Communications, 2018, 9, 4962.	5.8	111
128	Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. Journal of Hepatology, 2021, 75, 865-878.	1.8	111
129	Hepatic Fibrogenesis. Seminars in Liver Disease, 2007, 27, 413-426.	1.8	110
130	Stellate cells: A moving target in hepatic fibrogenesis. Hepatology, 2004, 40, 1041-1043.	3.6	109
131	A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection. Gut, 2016, 65, 1754-1764.	6.1	108
132	Reduced Nicotinamide Adenine Dinucleotide Phosphate Oxidase 2 Plays a Key Role in Stellate Cell Activation and Liver Fibrogenesis In Vivo. Gastroenterology, 2010, 139, 1375-1384.e4.	0.6	105
133	Roles of KLF6 and KLF6-SV1 in Ovarian Cancer Progression and Intraperitoneal Dissemination. Clinical Cancer Research, 2006, 12, 3730-3739.	3.2	103
134	Amelioration of hepatic fibrosis by NK cell activation. Gut, 2011, 60, 90-98.	6.1	102
135	IL-17A Enhances the Expression of Profibrotic Genes through Upregulation of the TGF-Î² Receptor on Hepatic Stellate Cells in a JNK-Dependent Manner. Journal of Immunology, 2014, 193, 3925-3933.	0.4	101
136	Mechanism of retarded liver regeneration in plasminogen activator-deficient mice: Impaired activation of hepatocyte growth factor after Fas-mediated massive hepatic apoptosis. Hepatology, 2001, 33, 569-576.	3.6	100
137	Interleukin-6 protects hepatocytes from CCl4-mediated necrosis and apoptosis in mice by reducing MMP-2 expression. Journal of Hepatology, 2005, 42, 548-556.	1.8	100
138	Kupffer cell activation by ambient air particulate matter exposure may exacerbate non-alcoholic fatty liver disease. Journal of Immunotoxicology, 2009, 6, 266-275.	0.9	100
139	Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial. Nature Medicine, 2021, 27, 1825-1835.	15.2	98
140	KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. Journal of Clinical Investigation, 2008, 118, 2711-2721.	3.9	97
141	Ras Promotes Growth by Alternative Splicing-Mediated Inactivation of the KLF6 Tumor Suppressor in Hepatocellular Carcinoma. Gastroenterology, 2008, 134, 1521-1531.	0.6	96
142	Immunomodulatory Effects of Lenvatinib Plus Antiâ€“Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma. Hepatology, 2021, 74, 2652-2669.	3.6	95
143	Prevalence and Profile of Nonalcoholic Fatty Liver Disease in Lean Adults: Systematic Review and Metaâ€Analysis. Hepatology Communications, 2020, 4, 953-972.	2.0	93
144	Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification. Gut, 2023, 72, 129-140.	6.1	90

#	Article	IF	Citations
145	Differential expression of transforming growth factor-Î² isoforms and receptors in experimental membranous nephropathy. Kidney International, 1996, 50, 116-124.	2.6	89
146	Cellular basis of hepatic fibrosis and its role in inflammation and cancer. Frontiers in Bioscience - Scholar, 2013, S5, 217-230.	0.8	89
147	A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma. Oncogene, 2018, 37, 3740-3752.	2.6	89
148	Autophagy fuels tissue fibrogenesis. Autophagy, 2012, 8, 849-850.	4.3	86
149	Granulocyte macrophage colony-stimulating factor is required for aortic dissection/intramural haematoma. Nature Communications, 2015, 6, 6994.	5.8	86
150	Precision-Cut Liver Slices as a New Model to Study Toxicity-Induced Hepatic Stellate Cell Activation in a Physiologic Milieu. Toxicological Sciences, 2005, 85, 632-638.	1.4	85
151	Suppression of glioblastoma tumorigenicity by the Kruppel-like transcription factor KLF6. Oncogene, 2004, 23, 5077-5083.	2.6	84
152	A histone deacetylase inhibitor, largazole, decreases liver fibrosis and angiogenesis by inhibiting transforming growth factorâ€Î² and vascular endothelial growth factor signalling. Liver International, 2013, 33, 504-515.	1.9	84
153	Focus. Journal of Hepatology, 2012, 56, 1-3.	1.8	82
154	Lhx2-/- mice develop liver fibrosis. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 16549-16554.	3.3	81
155	Advances in antifibrotic therapy. Expert Review of Gastroenterology and Hepatology, 2008, 2, 803-816.	1.4	81
156	Emerging and Disease-Specific Mechanisms of Hepatic Stellate Cell Activation. Seminars in Liver Disease, 2015, 35, 107-118.	1.8	81
157	Mechanisms of Nitric Oxide Interplay with Rho GTPase Family Members in Modulation of Actin Membrane Dynamics in Pericytes and Fibroblasts. American Journal of Pathology, 2005, 166, 1861-1870.	1.9	79
158	The LATS2 tumor suppressor inhibits SREBP and suppresses hepatic cholesterol accumulation. Genes and Development, 2016, 30, 786-797.	2.7	78
159	Downregulation of hepatic stellate cell activation by retinol and palmitate mediated by adipose differentiationâ€related protein (ADRP). Journal of Cellular Physiology, 2010, 223, 648-657.	2.0	77
160	The XBP1 Arm of the Unfolded Protein Response Induces Fibrogenic Activity in Hepatic Stellate Cells Through Autophagy. Scientific Reports, 2016, 6, 39342.	1.6	77
161	Î²-Blockade Therapy for Supraventricular Tachyarrhythmias After Coronary Surgery: A Propranolol Withdrawal Syndrome?. Angiology, 1979, 30, 816-819.	0.8	75
162	Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. Journal of Hepatology, 2007, 46, 645-654.	1.8	75

#	Article	IF	Citations
163	Antifibrotic Therapies: Where Are We Now?. Seminars in Liver Disease, 2016, 36, 087-098.	1.8	75
164	Increased 9,13-di-cis-retinoic acid in rat hepatic fibrosis: implication for a potential link between retinoid loss and TGF-Î² mediated fibrogenesis in vivo. Journal of Hepatology, 1999, 30, 1073-1080.	1.8	74
165	Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer. Current Opinion in Oncology, 2014, 26, 100-107.	1.1	74
166	Functional inactivation of the KLF6 tumor suppressor gene by loss of heterozygosity and increased alternative splicing in glioblastoma. International Journal of Cancer, 2007, 121, 1390-1395.	2.3	73
167	Mac the knife? Macrophagesâ€“ the double-edged sword of hepatic fibrosis. Journal of Clinical Investigation, 2005, 115, 29-32.	3.9	73
168	Î²-Catenin signaling in hepatocellular cancer: Implications in inflammation, fibrosis, and proliferation. Cancer Letters, 2014, 343, 90-97.	3.2	71
169	Loss of Matrix Metalloproteinase-2 Amplifies Murine Toxin-Induced Liver Fibrosis by Upregulating CollagenÂI Expression. Digestive Diseases and Sciences, 2011, 56, 406-416.	1.1	70
170	A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. Gut, 2015, 64, 1296-1302.	6.1	70
171	Hepatic fibrosis--role of hepatic stellate cell activation. MedGenMed: Medscape General Medicine, 2002, 4, 27.	0.2	70
172	Prostaglandin E2 inhibits transforming growth factor Î²1-mediated induction of collagen Î±1(I) in hepatic stellate cells. Journal of Hepatology, 2004, 41, 251-258.	1.8	69
173	Parathyroid hormone induces hepatic production of bioactive interleukin-6 and its soluble receptor. American Journal of Physiology - Endocrinology and Metabolism, 2001, 280, E405-E412.	1.8	68
174	Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC. Clinical and Translational Gastroenterology, 2020, 11, e00131.	1.3	68
175	Multiple variants in toll-like receptor 4 gene modulate risk of liver fibrosis in Caucasians with chronic hepatitis C infection. Journal of Hepatology, 2009, 51, 750-757.	1.8	67
176	Discoidin domain receptor 2 deficiency predisposes hepatic tissue to colon carcinoma metastasis. Gut, 2012, 61, 1465-1472.	6.1	66
177	Intravenous Cyclosporine in Refractory Pyoderma Gangrenosum Complicating Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2001, 7, 1-7.	0.9	65
178	Molecular mechanism for growth suppression of human hepatocellular carcinoma cells by acyclic retinoid. Carcinogenesis, 2003, 24, 1353-1359.	1.3	65
179	Therapeutic targeting of the PDGF and TGF-Î²-signaling pathways in hepatic stellate cells by PTK787/ZK22258. Laboratory Investigation, 2009, 89, 1152-1160.	1.7	65
180	CD11b⁺Gr1⁺bone marrow cells ameliorate liver fibrosis by producing interleukin-10 in mice. Hepatology, 2012, 56, 1902-1912.	3.6	65

#	Article	IF	Citations
181	Hepatic Fibrosis: Emerging Therapies. Digestive Diseases, 2015, 33, 504-507.	0.8	65
182	The KrÃ¼ppel-like transcriptional factors Zf9 and GKLF coactivate the human keratin 4 promoter and physically interact. FEBS Letters, 2000, 473, 95-100.	1.3	64
183	Genome-wide transcriptome analysis identifies novel gene signatures implicated in human chronic liver disease. American Journal of Physiology - Renal Physiology, 2013, 305, G364-G374.	1.6	63
184	Distinct from its canonical effects, deletion of IL-12p40 induces cholangitis and fibrosis in interleukin-2RÎ±â^'/â^' mice. Journal of Autoimmunity, 2014, 51, 99-108.	3.0	62
185	An Immune Gene Expression Signature Associated With Development of Human Hepatocellular Carcinoma Identifies Mice That Respond to Chemopreventive Agents. Gastroenterology, 2019, 157, 1383-1397.e11.	0.6	62
186	Phosphorylation of retinoid X receptor suppresses its ubiquitination in human hepatocellular carcinoma. Hepatology, 2002, 35, 332-340.	3.6	61
187	Integrin alpha 11 in the regulation of the myofibroblast phenotype: implications for fibrotic diseases. Experimental and Molecular Medicine, 2017, 49, e396-e396.	3.2	61
188	Using Big Data to Discover Diagnostics and Therapeutics forÂGastrointestinal and Liver Diseases. Gastroenterology, 2017, 152, 53-67.e3.	0.6	61
189	Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014. Hepatology, 2015, 62, 627-634.	3.6	60
190	Why Do So Many Nonalcoholic Steatohepatitis Trials Fail?. Gastroenterology, 2023, 165, 5-10.	0.6	59
191	Kupffer cell activation by ambient air particulate matter exposure may exacerbate non-alcoholic fatty liver disease. Journal of Immunotoxicology, 2009, 00, 090924084432057-10.	0.9	59
192	Hepatitis Outreach Network: A practical strategy for hepatitis screening with linkage to care in foreign-born communities. Journal of Hepatology, 2013, 58, 890-897.	1.8	58
193	Fibrosis Regression After Eradication of Hepatitis C Virus: From Bench to Bedside. Gastroenterology, 2021, 160, 1502-1520.e1.	0.6	58
194	Hepatocyte Growth Factor Enhances Alternative Splicing of the KrÃ¼ppel-like Factor 6 (KLF6) Tumor Suppressor to Promote Growth through SRSF1. Molecular Cancer Research, 2012, 10, 1216-1227.	1.5	57
195	Early genes induced in hepatic stellate cells during wound healing. Gene, 1997, 195, 235-243.	1.0	56
196	Transcriptional Activation of the Insulin-Like Growth Factor I Receptor Gene by the Kruppel-Like Factor 6 (KLF6) Tumor Suppressor Protein: Potential Interactions between KLF6 and p53. Endocrinology, 2004, 145, 3769-3777.	1.4	56
197	Hepatic Fibrosis and the Microenvironment: Fertile Soil for Hepatocellular Carcinoma Development. Gene Expression, 2014, 16, 77-84.	0.5	56
198	Glucokinase links KrÃ¼ppel-like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver disease. Hepatology, 2012, 55, 1083-1093.	3.6	55

#	Article	IF	Citations
199	Convergent pathways that cause hepatic fibrosis in NASH. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 71-72.	8.2	54
200	Vascular Injury Triggers KrÃ¼ppel-Like Factor 6 Mobilization and Cooperation With Specificity Protein 1 to Promote Endothelial Activation Through Upregulation of the Activin Receptor-Like Kinase 1 Gene. Circulation Research, 2013, 112, 113-127.	2.0	54
201	Prospective comparison of magnetic resonance imaging to transient elastography and serum markers for liver fibrosis detection. Liver International, 2016, 36, 659-666.	1.9	54
202	Regulation of KrÃ¼ppel-like Factor 6 Tumor Suppressor Activity by Acetylation. Cancer Research, 2005, 65, 9216-9225.	0.4	53
203	Genetic Characteristics of the Human Hepatic Stellate Cell Line LX-2. PLoS ONE, 2013, 8, e75692.	1.1	53
204	Loss of Discoidin Domain Receptor 2 Promotes Hepatic Fibrosis after Chronic Carbon Tetrachloride through Altered Paracrine Interactions between Hepatic Stellate Cells and Liver-Associated Macrophages. American Journal of Pathology, 2011, 179, 2894-2904.	1.9	52
205	Transcription factor KLF6 upregulates expression of metalloprotease MMP14 and subsequent release of soluble endoglin during vascular injury. Angiogenesis, 2016, 19, 155-171.	3.7	52
206	Serum biomarkers can predict a change in liver fibrosis 1Âyear after lifestyle intervention for biopsyâ€proven <scp>NASH</scp>. Liver International, 2017, 37, 1887-1896.	1.9	52
207	Programmed cell deathâ€1 blockade enhances response to stereotactic radiation in an orthotopic murine model of hepatocellular carcinoma. Hepatology Research, 2017, 47, 702-714.	1.8	52
208	Antifibrotic Activity of Sorafenib in Experimental Hepatic Fibrosis: Refinement of Inhibitory Targets, Dosing, and Window of Efficacy In Vivo. Digestive Diseases and Sciences, 2013, 58, 257-64.	1.1	50
209	Post-transcriptional activation of PPAR alpha by KLF6 in hepatic steatosis. Journal of Hepatology, 2013, 58, 1000-1006.	1.8	50
210	Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention. Hepatology, 2016, 63, 1875-1887.	3.6	50
211	Parenchymal and Nonparenchymal Cell Interactions in the Liver. Seminars in Liver Disease, 1993, 13, 13-20.	1.8	49
212	New and emerging anti-fibrotic therapeutics entering or already in clinical trials in chronic liver diseases. Current Opinion in Pharmacology, 2019, 49, 60-70.	1.7	49
213	SYSTEMIC AMYLOIDOSIS AND THE GASTROINTESTINAL TRACT. Gastroenterology Clinics of North America, 1998, 27, 595-614.	1.0	48
214	Molecular Diagnosis of Chronic Liver Disease and Hepatocellular Carcinoma: The Potential of Gene Expression Profiling. Seminars in Liver Disease, 2006, 26, 373-384.	1.8	48
215	Functional role of the KLF6 tumour suppressor gene in gastric cancer. European Journal of Cancer, 2009, 45, 666-676.	1.3	48
216	Human hepatic stellate cell line (LX-2) exhibits characteristics of bone marrow-derived mesenchymal stem cells. Experimental and Molecular Pathology, 2011, 91, 664-672.	0.9	48

#	Article	IF	Citations
217	Synergistic induction of apoptosis by acyclic retinoid and interferon-Î² in human hepatocellular carcinoma cells. Hepatology, 2002, 36, 1115-1124.	3.6	47
218	Obesity, Inflammatory Signaling, and Hepatocellular Carcinomaâ€"An Enlarging Link. Cancer Cell, 2010, 17, 115-117.	7.7	47
219	Genomics and proteomics in liver fibrosis and cirrhosis. Fibrogenesis and Tissue Repair, 2012, 5, 1.	3.4	47
220	Nonalcoholic Steatohepatitis Is Associated With Increased Mortality in Obese Patients Undergoing Bariatric Surgery. Clinical Gastroenterology and Hepatology, 2016, 14, 1619-1628.	2.4	47
221	Central Role of Conventional Dendritic Cells in Regulation of Bone Marrow Release and Survival of Neutrophils. Journal of Immunology, 2014, 192, 3374-3382.	0.4	45
222	CCN1/CYR61 overexpression in hepatic stellate cells induces ER stress-related apoptosis. Cellular Signalling, 2016, 28, 34-42.	1.7	45
223	Hepatic Autophagy Deficiency Compromises Farnesoid X Receptor Functionality and Causes Cholestatic Injury. Hepatology, 2019, 69, 2196-2213.	3.6	45
224	Inflammatory and fibrotic mechanisms in NAFLDâ€"Implications for new treatment strategies. Journal of Internal Medicine, 2022, 291, 11-31.	2.7	45
225	Fibrogenic cell reversion underlies fibrosis regression in liver. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 9230-9231.	3.3	44
226	Gastrointestinal KaposiÊ¼s Sarcoma in AIDS. Journal of Clinical Gastroenterology, 1984, 6, 165-172.	1.1	43
227	Embryonic expression of KrÃ¼ppel-like factor 6 in neural and non-neural tissues. Mechanisms of Development, 2001, 106, 167-170.	1.7	43
228	Prevention of Rat Hepatocarcinogenesis by Acyclic Retinoid Is Accompanied by Reduction in Emergence of Both TGF-Î±-Expressing Oval-Like Cells and Activated Hepatic Stellate Cells. Nutrition and Cancer, 2005, 51, 197-206.	0.9	43
229	The In Ovo Chick Chorioallantoic Membrane (CAM) Assay as an Efficient Xenograft Model of Hepatocellular Carcinoma. Journal of Visualized Experiments, 2015, , .	0.2	43
230	p38â€MAPKâ€•and caspaseâ€3â€•mediated superoxideâ€•induced apoptosis of rat hepatic stellate cells: Reversal by retinoic acid. Journal of Cellular Physiology, 2009, 218, 157-166.	2.0	42
231	Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications. Gut, 2023, 72, 736-748.	6.1	42
232	KrÃ¼ppel Cripples Prostate Cancer. American Journal of Pathology, 2003, 162, 1047-1052.	1.9	41
233	Increased alternative splicing of the KLF6 tumour suppressor gene correlates with prognosis and tumour grade in patients with pancreatic cancer. European Journal of Cancer, 2008, 44, 1895-1903.	1.3	41
234	Mac the knife? Macrophagesâ€“ the double-edged sword of hepatic fibrosis. Journal of Clinical Investigation, 2005, 115, 29-32.	3.9	41

#	Article	IF	Citations
235	Transcriptional Regulation in Hepatic Stellate Cells. Seminars in Liver Disease, 2001, 21, 385-396.	1.8	40
236	Epithelial Xbp1 Is Required for Cellular Proliferation and Differentiation during Mammary Gland Development. Molecular and Cellular Biology, 2015, 35, 1543-1556.	1.1	40
237	Hepatic fibrosis: A convergent response to liver injury that is reversible. Journal of Hepatology, 2020, 73, 210-211.	1.8	40
238	Treatment of hepatic fibrosis: Almost there. Current Gastroenterology Reports, 2003, 5, 48-56.	1.1	39
239	Carcinogen-induced hepatic tumors in KLF6+/â^' mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation. Hepatology, 2011, 54, 522-531.	3.6	39
240	Liver Injury in Patients Hospitalized with Coronavirus Disease 2019 Correlates with Hyperinflammatory Response and Elevated Interleukinâ€6. Hepatology Communications, 2021, 5, 177-188.	2.0	39
241	Activation of rat hepatic stellate cells leads to loss of glutathionS-transferases and their enzymatic activity against products of oxidative stress. Hepatology, 1999, 30, 927-933.	3.6	38
242	Transcriptional regulation of stellate cell activation. Journal of Gastroenterology and Hepatology (Australia), 2006, 21, S79-S83.	1.4	38
243	<scp>SOX</scp> 9 predicts progression toward cirrhosis in patients while its loss protects against liver fibrosis. EMBO Molecular Medicine, 2017, 9, 1696-1710.	3.3	38
244	The RING Finger Protein, RNF8, Interacts with Retinoid X Receptor Î± and Enhances Its Transcription-stimulating Activity. Journal of Biological Chemistry, 2004, 279, 18926-18934.	1.6	37
245	Reduced hepatic stellate cell expression of kruppel-like factor 6 tumor suppressor isoforms amplifies fibrosis during acute and chronic rodent liver injury. Hepatology, 2013, 57, 786-796.	3.6	37
246	Modulation of cardiac fibrosis by KrÃ¼ppel-like factor 6 through transcriptional control of thrombospondin 4 in cardiomyocytes. Cardiovascular Research, 2015, 107, 420-430.	1.8	37
247	Fully automated prediction of liver fibrosis using deep learning analysis of gadoxetic acidâ€"enhanced MRI. European Radiology, 2021, 31, 3805-3814.	2.3	37
248	Commentary: Gastroenterology and Hepatology: An Evolving Marriage, Not an Imminent Divorce. American Journal of Gastroenterology, 2009, 104, 10-11.	0.2	36
249	Resveratrol amplifies profibrogenic effects of free fatty acids on human hepatic stellate cells. Hepatology Research, 2009, 39, 601-608.	1.8	36
250	SPARC downregulation attenuates the profibrogenic response of hepatic stellate cells induced by TGF-Î²₁and PDGF. American Journal of Physiology - Renal Physiology, 2011, 300, G739-G748.	1.6	36
251	Antiâ€fibrotic activity and enhanced interleukinâ€6 production by hepatic stellate cells in response to imatinib mesylate. Liver International, 2012, 32, 1008-1017.	1.9	35
252	E3 Ubiquitin Ligase Synoviolin Is Involved in Liver Fibrogenesis. PLoS ONE, 2010, 5, e13590.	1.1	35

#	Article	IF	Citations
253	KLF6 allelic loss is associated with tumor recurrence and markedly decreased survival in head and neck squamous cell carcinoma. International Journal of Cancer, 2007, 121, 1976-1983.	2.3	34
254	PTK787/ZK22258 attenuates stellate cell activation and hepatic fibrosis in vivo by inhibiting VEGF signaling. Laboratory Investigation, 2009, 89, 209-221.	1.7	33
255	Liver transplant for hepatocellular carcinoma in the United States: Evolving trends over the last three decades. American Journal of Transplantation, 2020, 20, 220-230.	2.6	33
256	A DDX5 S480A Polymorphism Is Associated with Increased Transcription of Fibrogenic Genes in Hepatic Stellate Cells. Journal of Biological Chemistry, 2010, 285, 5428-5437.	1.6	32
257	Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis. JHEP Reports, 2021, 3, 100237.	2.6	32
258	Enhanced hepatocarcinogenesis in mouse models and human hepatocellular carcinoma by coordinate KLF6 depletion and increased messenger RNA splicing. Hepatology, 2012, 56, 1361-1370.	3.6	31
259	Inhibition of the <scp>CXCL</scp>12/<scp>CXCR</scp>4 chemokine axis with <scp>AMD</scp>3100, a <scp>CXCR</scp>4 small molecule inhibitor, worsens murine hepatic injury. Hepatology Research, 2015, 45, 794-803.	1.8	31
260	The Transcriptional Activator KrÃ¼ppel-like Factor-6 Is Required for CNS Myelination. PLoS Biology, 2016, 14, e1002467.	2.6	31
261	Acetaldehyde and alcoholic fibrogenesis: Fuel to the fire, but not the spark. Hepatology, 1990, 12, 609-612.	3.6	30
262	KLF6 degradation after apoptotic DNA damage. FEBS Letters, 2006, 580, 6981-6986.	1.3	30
263	Treatment of cholestatic fibrosis by altering gene expression of Cthrc1: Implications for autoimmune and non-autoimmune liver disease. Journal of Autoimmunity, 2015, 63, 76-87.	3.0	30
264	Interleukin-15 receptor Î± on hepatic stellate cells regulates hepatic fibrogenesis in mice. Journal of Hepatology, 2016, 65, 344-353.	1.8	30
265	SOX9 regulated matrix proteins are increased in patients serum and correlate with severity of liver fibrosis. Scientific Reports, 2018, 8, 17905.	1.6	30
266	Modeling dysbiosis of human NASH in mice: Loss of gut microbiome diversity and overgrowth of Erysipelotrichales. PLoS ONE, 2021, 16, e0244763.	1.1	30
267	Hepatic Stellate Cell-Immune Interactions in NASH. Frontiers in Endocrinology, 0, 13, .	1.5	30
268	Beneficial effect of glatiramer acetate (Copaxone) on immune modulation of experimental hepatic fibrosis. American Journal of Physiology - Renal Physiology, 2007, 292, G628-G638.	1.6	29
269	Fibrosis in the Liver. Progress in Molecular Biology and Translational Science, 2010, 97, 151-200.	0.9	29
270	Transcriptome-based repurposing of apigenin as a potential anti-fibrotic agent targeting hepatic stellate cells. Scientific Reports, 2017, 7, 42563.	1.6	29

#	Article	IF	Citations
271	KrÃ¼ppel-like factor 6 is a transcriptional activator of autophagy in acute liver injury. Scientific Reports, 2017, 7, 8119.	1.6	29
272	A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage. JHEP Reports, 2020, 2, 100064.	2.6	29
273	Liver fibrosis: from mechanisms to treatment. Gastroenterologie Clinique Et Biologique, 2007, 31, 812-814.	0.9	28
274	Klf6/copeb is required for hepatic outgrowth in zebrafish and for hepatocyte specification in mouse ES cells. Developmental Biology, 2010, 344, 79-93.	0.9	28
275	Evidence that Sp1 positively and Sp3 negatively regulate and androgen does not directly regulate functional tumor suppressor 15-lipoxygenase 2 (15-LOX2) gene expression in normal human prostate epithelial cells. Oncogene, 2004, 23, 6942-6953.	2.6	27
276	A polymorphism that delays fibrosis in hepatitis C promotes alternative splicing of AZIN1, reducing fibrogenesis. Hepatology, 2011, 54, 2198-2207.	3.6	27
277	High mobility group box 1 activates toll like receptor 4 signaling in hepatic stellate cells. Life Sciences, 2012, 91, 207-212.	2.0	27
278	Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population. Journal of Hepatology, 2021, 75, 1292-1300.	1.8	27
279	Cytoskeleton of liver perisinusoidal cells (lipocytes) in normal and pathological conditions. Cytoskeleton, 1992, 22, 227-234.	4.4	26
280	Cellular Networks in Hepatic Fibrosis. Digestion, 1998, 59, 368-371.	1.2	26
281	Reversibility of hepatic fibrosis and cirrhosisâ€"is it all hype?. Nature Reviews Gastroenterology & Hepatology, 2007, 4, 236-237.	1.7	26
282	Mannose Phosphate Isomerase and Mannose Regulate Hepatic Stellate Cell Activation and Fibrosis in Zebrafish and Humans. Hepatology, 2019, 70, 2107-2122.	3.6	26
283	Neoplasms of the Gastrointestinal Tract and Hepatobiliary System in Acquired Immunodeficiency Syndrome. Seminars in Liver Disease, 1992, 12, 128-141.	1.8	25
284	Aging Suppresses Sphingosine-1-Phosphate Chaperone ApoM in Circulation Resulting in Maladaptive Organ Repair. Developmental Cell, 2020, 53, 677-690.e4.	3.1	25
285	A deer in the headlights: BAMBI meets liver fibrosis. Nature Medicine, 2007, 13, 1281-1282.	15.2	24
286	Reactive oxygen species and NADPH oxidase 4 induced by transforming growth factor Î²1 are the therapeutic targets of polyenylphosphatidylcholine in the suppression of human hepatic stellate cell activation. Inflammation Research, 2011, 60, 597-604.	1.6	24
287	Targeting epigenetically maladapted vascular niche alleviates liver fibrosis in nonalcoholic steatohepatitis. Science Translational Medicine, 2021, 13, eabd1206.	5.8	24
288	Kaposi's sarcoma and lymphoma of the gut in AIDS. Bailliere's Clinical Gastroenterology, 1990, 4, 455-475.	0.9	23

#	Article	IF	Citations
289	Targeted and regulable expression of transgenes in hepatic stellate cells and myofibroblasts in culture and in vivo using an adenoviral Cre/loxP system to antagonise hepatic fibrosis. Gut, 2007, 56, 396-404.	6.1	23
290	LAP degradation product reflects plasma kallikrein-dependent TGF-Î² activation in patients with hepatic fibrosis. SpringerPlus, 2014, 3, 221.	1.2	23
291	Stellate cell apoptosis by a soluble mediator from immortalized human hepatocytes. Apoptosis: an International Journal on Programmed Cell Death, 2006, 11, 1391-1400.	2.2	22
292	Tumor suppressor activity of KLF6 mediated by downregulation of the PTTG1 oncogene. FEBS Letters, 2010, 584, 1006-1010.	1.3	22
293	Preface. Clinics in Liver Disease, 2008, 12, xiii-xiv.	1.0	21
294	Acute Liver Injury and Decompensated Cirrhosis. Medical Clinics of North America, 2020, 104, 647-662.	1.1	21
295	CARDIOVASCULAR TOLERANCE IN UNSEDATED UPPER GASTROINTESTINAL ENDOSCOPY: PROSPECTIVE RANDOMIZED COMPARISON BETWEEN TRANSNASAL AND CONVENTIONAL ORAL PROCEDURES. Digestive Endoscopy, 2006, 18, 282-287.	1.3	20
296	Slit2-Robo2 signaling modulates the fibrogenic activity and migration of hepatic stellate cells. Life Sciences, 2018, 203, 39-47.	2.0	20
297	Mechanisms of Liver Fibrosis Associated with Experimental Fasciola hepatica Infection: Roles of Fas2 Proteinase and Hepatic Stellate Cell Activation. Journal of Parasitology, 2011, 97, 82.	0.3	19
298	Alcohol and inflammatory responses: Summary of the 2013 Alcohol and Immunology Research Interest Group (AIRIG) meeting. Alcohol, 2015, 49, 1-6.	0.8	19
299	Transcriptomic analysis of the effects of Toll-like receptor 4 and its ligands on the gene expression network of hepatic stellate cells. Fibrogenesis and Tissue Repair, 2016, 9, 2.	3.4	19
300	Sex steroids have differential effects on growth and gene expression in primary human prostatic epithelial cell cultures derived from the peripheral versus transition zones. Carcinogenesis, 2006, 27, 216-224.	1.3	18
301	Insulin-Like Growth Factor-I Regulates Kruì¨ppel-Like Factor-6 Gene Expression in a p53-Dependent Manner. Endocrinology, 2008, 149, 1890-1897.	1.4	18
302	Risk Factors for Hepatocellular Carcinoma in Cirrhotic Patients with Chronic Hepatitis B. Genetic Testing and Molecular Biomarkers, 2016, 20, 535-543.	0.3	18
303	Enhanced Oral Tolerance in Transgenic Mice with Hepatocyte Secretion of IL-10. Journal of Immunology, 2005, 175, 3577-3583.	0.4	17
304	CXCL12 induces hepatic stellate cell contraction through a calcium-independent pathway. American Journal of Physiology - Renal Physiology, 2013, 305, G375-G382.	1.6	17
305	Focus. Journal of Hepatology, 2014, 60, 1-2.	1.8	17
306	Molecular Signature Predictive of Long-Term Liver Fibrosis Progression to Inform Antifibrotic Drug Development. Gastroenterology, 2022, 162, 1210-1225.	0.6	17

#	Article	IF	Citations
307	Diagnosis of Hepatic Fibrosis in Patients with Chronic Hepatitis C. Clinics in Liver Disease, 2006, 10, 821-833.	1.0	16
308	Autophagy and mesenchymal cell fibrogenesis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 972-978.	1.8	16
309	Altered global microRNA expression in hepatic stellate cells LX-2 by angiotensin-(1â€“7) and miRNA-1914-5p identification as regulator of pro-fibrogenic elements and lipid metabolism. International Journal of Biochemistry and Cell Biology, 2018, 98, 137-155.	1.2	16
310	Extensive Health Care Utilization and Costs of an Early Liver Transplantation Program for Alcoholic Hepatitis. Liver Transplantation, 2022, 28, 27-38.	1.3	16
311	Immunopathogenesis of hepatitis C virus infection and hepatic fibrosis: New insights into antifibrotic therapy in chronic hepatitis C. Hepatology Research, 2007, 37, 579-595.	1.8	15
312	Targeting siRNA to arrest fibrosis. Nature Biotechnology, 2008, 26, 399-400.	9.4	15
313	Late intervention with the small molecule BB3 mitigates postischemic kidney injury. American Journal of Physiology - Renal Physiology, 2016, 311, F352-F361.	1.3	15
314	Murine deficiency of peroxisomal l-bifunctional protein (EHHADH) causes medium-chain 3-hydroxydicarboxylic aciduria and perturbs hepatic cholesterol homeostasis. Cellular and Molecular Life Sciences, 2021, 78, 5631-5646.	2.4	15
315	A splice variant of ADAMTS13 is expressed in human hepatic stellate cells and cancerous tissues. Thrombosis and Haemostasis, 2010, 104, 531-533.	1.8	14
316	Induction and contribution of beta plateletâ€derived growth factor signalling by hepatic stellate cells to liver regeneration after partial hepatectomy in mice. Liver International, 2016, 36, 874-882.	1.9	14
317	Experimental and Investigational Targeted Therapies for the Management of Fibrosis in NASH: An Update. Journal of Experimental Pharmacology, 2021, Volume 13, 329-338.	1.5	14
318	Stellate Cells and Hepatic Fibrosis. , 2015, , 41-62.		13
319	KLF6 Gene and Early Melanoma Development in a Collagen I-Rich Extracellular Environment. Journal of the National Cancer Institute, 2010, 102, 1131-1147.	3.0	12
320	Increased expression of the oncogenic KLF6-SV1 transcript in human glioblastoma. Clinical Chemistry and Laboratory Medicine, 2010, 48, 1167-1170.	1.4	12
321	Focus. Journal of Hepatology, 2013, 58, 1-2.	1.8	12
322	Transporting pharmacogenomics into clinical practice. Journal of Hepatology, 2014, 61, 1-2.	1.8	12
323	Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative. Liver International, 2020, 40, 2860-2876.	1.9	12
324	Activation of Hepatic Stellate Cells Requires Dissociation of E-Cadherinâ€“Containing Adherens Junctions with Hepatocytes. American Journal of Pathology, 2021, 191, 438-453.	1.9	12

#	Article	IF	Citations
325	The peroxisomal transporter <scp>ABCD3</scp> plays a major role in hepatic dicarboxylic fatty acid metabolism and lipid homeostasis. Journal of Inherited Metabolic Disease, 2021, 44, 1419-1433.	1.7	12
326	Autophagy-Related Activation of Hepatic Stellate Cells Reduces Cellular miR-29a by Promoting Its Vesicular Secretion. Cellular and Molecular Gastroenterology and Hepatology, 2022, 13, 1701-1716.	2.3	12
327	Reply:. Hepatology, 2005, 41, 682-683.	3.6	11
328	Genetic Characterization of Rat Hepatic Stellate Cell Line HSC-T6 for In Vitro Cell Line Authentication. Cells, 2022, 11, 1783.	1.8	11
329	â€œCuts both waysâ€• Collagenases, lipocyte activation and polyunsaturated lecithin. Hepatology, 1992, 15, 549-551.	3.6	10
330	Hepatic Fibrosis and Cirrhosis. , 2012, , 64-85.		10
331	L59 TGF-Î² LAP degradation products serve as a promising blood biomarker for liver fibrogenesis in mice. Fibrogenesis and Tissue Repair, 2015, 8, 17.	3.4	10
332	Fighting Cardiac Fibrosis with CAR T Cells. New England Journal of Medicine, 2022, 386, 1576-1578.	13.9	10
333	The Role of Inflammation and Immunity in the Pathogenesis of Liver Fibrosis. , 2007, , 111-121.		9
334	Dendritic Cells in Alcoholic Liver Injury and Fibrosis. Alcoholism: Clinical and Experimental Research, 2011, 35, 776-781.	1.4	9
335	A Candidate Gene Study for the Association of Host Single Nucleotide Polymorphisms with Liver Cirrhosis Risk in Chinese Hepatitis B Patients. Genetic Testing and Molecular Biomarkers, 2013, 17, 681-686.	0.3	9
336	Ligand-Dependent Corepressor (LCoR) Is a Rexinoid-Inhibited Peroxisome Proliferator-Activated Receptor Î³â€“Retinoid X Receptor Î± Coactivator. Molecular and Cellular Biology, 2018, 38, .	1.1	9
337	Parenchymal FE and collagen gene expression: An iron-clad association?. Hepatology, 1995, 21, 1197-1199.	3.6	8
338	On the â€œTrue-Falseâ€•Memory Syndrome: The Problem of Clinical Evidence. American Journal of Psychotherapy, 1997, 51, 102-122.	0.4	8
339	Hepatic Fibrosis and Cirrhosis. , 2006, , 87-109.		8
340	Shared and Tissue-Specific Expression Signatures between Bone Marrow from Primary Myelofibrosis and Essential Thrombocythemia. Experimental Hematology, 2019, 79, 16-25.e3.	0.2	8
341	Antifibrotic Effects of Amyloid-Beta and Its Loss in Cirrhotic Liver. Cells, 2020, 9, 452.	1.8	8
342	Detection of a secreted metalloprotease within the nuclei of liver cells. Molecular BioSystems, 2011, 7, 2012.	2.9	7

#	Article	IF	Citations
343	The Expression Patterns and Clinical Significance of microRNAs in Liver Diseases and Hepatocellular Carcinoma. Current Pharmaceutical Design, 2012, 19, 1262-1272.	0.9	7
344	Noninvasive diagnosis of portal hypertension using gadoxetate DCE-MRI of the liver and spleen. European Radiology, 2021, 31, 4804-4812.	2.3	7
345	Ten Thousand Points of Light: Heterogeneity Among the Stars of NASH Fibrosis. Hepatology, 2021, 74, 543-546.	3.6	7
346	Antiâ€TNFÎ± treatment in Crohnâ€™s disease: Impact on hepatic steatosis, gutâ€derived hormones and metabolic status. Liver International, 2021, 41, 2646-2658.	1.9	7
347	Repositioning of a novel GABA-B receptor agonist, AZD3355 (Lesogaberan), for the treatment of non-alcoholic steatohepatitis. Scientific Reports, 2021, 11, 20827.	1.6	7
348	Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results. World Journal of Virology, 2017, 6, 59-72.	1.3	7
349	Cannabinoids Provoke Alcoholic Steatosis through a Conspiracy of Neighbors. Cell Metabolism, 2008, 7, 187-188.	7.2	6
350	Basic science to clinical trials in non-alcoholic fatty liver disease and alcohol-related liver disease: collaboration with industry. Translational Gastroenterology and Hepatology, 2021, 6, 5-5.	1.5	6
351	The answer: angiotensin II. The question: what do inflammation, oxidant stress and fibrogenesis have in common?. Journal of Hepatology, 2004, 40, 1050-1052.	1.8	5
352	Platelets arrive at the scene of fibrosisâ€¦â€¦studies. Journal of Hepatology, 2011, 54, 1063-1065.	1.8	5
353	Focus. Journal of Hepatology, 2013, 58, 845-846.	1.8	5
354	Preserved Expression of mRNA Coding von Willebrand Factor-Cleaving Protease ADAMTS13 by Selenite and Activated Protein C. Molecular Medicine, 2015, 21, 355-363.	1.9	5
355	A Sabbatical: The Gift That Keeps on Giving. Cellular and Molecular Gastroenterology and Hepatology, 2018, 5, 656-658.	2.3	5
356	MRI is the most commonly used imaging modality for HCC screening at a tertiary care transplant center. Abdominal Radiology, 2021, 46, 5142-5151.	1.0	5
357	Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus. World Journal of Gastroenterology, 2016, 22, 2844.	1.4	5
358	Spermidine Supplementation Protects the Liver Endothelium from Liver Damage in Mice. Nutrients, 2021, 13, 3700.	1.7	5
359	Excess iron into hepatocytes is required for activation of collagen I gene during experimental siderosis Gualdi R, Casalgrandi G, Moniosi G, Ventura E, Pietrangelo A. Gastroenterology 107:1118?1234, 1994. Hepatology, 1995, 21, 1197-1199.	3.6	4
360	Focus. Journal of Hepatology, 2011, 55, 1-2.	1.8	4

#	Article	IF	Citations
361	Focus. Journal of Hepatology, 2012, 57, 1-2.	1.8	4
362	Association of Genetic Variants With Rapid Fibrosis. Transplantation, 2014, 97, 1072-1078.	0.5	4
363	Protect thee from the sins of thy fathers?. Nature Medicine, 2012, 18, 1331-1332.	15.2	3
364	Focusing on the past, present, and future of hepatology. Journal of Hepatology, 2014, 61, 1196-1198.	1.8	3
365	Devilish Effects of Taz in Nonalcoholic Steatohepatitis. Cell Metabolism, 2016, 24, 771-772.	7.2	3
366	Hepatocyte KLF6 expression affects FXR signalling and the clinical course of primary sclerosing cholangitis. Liver International, 2020, 40, 2172-2181.	1.9	3
367	Extracellular Matrix. , 2010, , 93-104.		3
368	Downregulation of matrix and ?-PDGF receptor gene expression by anti-TGF? antibody in rat hepatic stellate cells during experimental liver injury. International Hepatology Communications, 1997, 6, 144-152.	0.7	2
369	Focus. Journal of Hepatology, 2012, 56, 1001-1002.	1.8	2
370	Focus. Journal of Hepatology, 2012, 57, 481-483.	1.8	2
371	Focus. Journal of Hepatology, 2012, 57, 935-936.	1.8	2
372	Focus. Journal of Hepatology, 2013, 59, 1-2.	1.8	2
373	Primary Non-Function. , 2014, , 462-468.		2
374	Replacing a crystal ball with a calculator in predicting liver disease outcomes. Journal of Hepatology, 2014, 60, 905-906.	1.8	2
375	â€œThere are decades where nothing happens; and there are weeks where decades happenâ€•â€“ Vladimir Ilyich Lenin. Journal of Hepatology, 2014, 60, 471-472.	1.8	2
376	Reply. Gastroenterology, 2015, 149, 1988-1989.	0.6	2
377	Megatrends in bile acid receptor research. Hepatology Communications, 2017, 1, 831-835.	2.0	2
378	A small molecule fibrokinase inhibitor in a model of fibropolycystic hepatorenal disease. World Journal of Nephrology, 2018, 7, 96-107.	0.8	2

#	Article	IF	Citations
379	Clarity and Challenges in Tissue Fibrosis. , 2015, , 187-194.		2
380	KrÃ¼ppel-like Factors and the Liver. , 2009, , 141-150.		2
381	Divergent roles of tumor suppressor gene Klf6 in ES cell differentiation. Journal of Electrophoresis, 2008, 52, 65-69.	0.2	2
382	The Immunopathogenesis of Cirrhosis. , 2014, , 413-424.		2
383	The enlarging role of matrix metalloproteinases in liver injury â€“ beyond scar degradation. Journal of Hepatology, 2002, 37, 293-294.	1.8	1
384	Extracellular Matrix. , 2005, , 63-71.		1
385	Reefer madness? Assessing the effects of cannabinoids with a less jaundiced eye. Journal of Hepatology, 2007, 46, 180-182.	1.8	1
386	Fibrosis as a Major Mechanism of Chronic Liver Disease. , 2011, , 91-107.		1
387	Focus. Journal of Hepatology, 2011, 55, 503-504.	1.8	1
388	Focus. Journal of Hepatology, 2011, 55, 953-954.	1.8	1
389	Focus. Journal of Hepatology, 2012, 56, 511-512.	1.8	1
390	Hepatitis B and D. , 2014, , 41-57.		1
391	Nutrition in Liver Diseases. , 2014, , 344-350.		1
392	Taming the Savage Breast From Within: Transcription Factor 21, a Regulator of Stellate Cell Deactivation. Hepatology, 2020, 71, 1150-1153.	3.6	1
393	KLF6 POLYMORPHISM IN PROSTATE CANCER REVEALS A NOVEL MECHANISM OF TUMOR SUPPRESSOR GENE INACTIVATION.. Journal of Investigative Medicine, 2003, 51, 336-337.	0.7	0
394	Antifibrotic targets and therapy in HCV. Current Hepatitis Reports, 2005, 4, 61-67.	0.3	0
395	Antifibrotic targets and therapy in HCV. Current Hepatitis Reports, 2006, 5, 94-100.	0.3	0
396	Activation of Ras/MAPK and mTOR pathways in hepatocellular carcinoma: Tumor growth inhibition with Ras/mTOR pathway abrogation by a novel combination of Sorafenib and rapamycin. Journal of the American College of Surgeons, 2007, 205, S93-S94.	0.2	0

#	Article	IF	Citations
397	110 MOLECULAR AND CLINICAL CHARACTERIZATION OF RICTOR (MTORC2) AS A CANDIDATE ONCOGENE IN HEPATOCELLULAR CARCINOMA. Journal of Hepatology, 2009, 50, S45.	1.8	0
398	Focus. Journal of Hepatology, 2011, 54, 841-843.	1.8	0
399	Liver fibrogenesis. , 2012, , 102-112.e4.		0
400	Focus. Journal of Hepatology, 2013, 59, 403-404.	1.8	0
401	Focus. Journal of Hepatology, 2013, 59, 915-917.	1.8	0
402	Preface to BBA issue devoted to fibrosis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 865.	1.8	0
403	Focus. Journal of Hepatology, 2013, 58, 407-408.	1.8	0
404	Hepatitis C: Diagnosis, Management and Treatment. , 2014, , 58-77.		0
405	Hereditary Hemochromatosis. , 2014, , 167-175.		0
406	Portal Hypertensive Bleeding. , 2014, , 196-208.		0
407	Hepatitis A and E. , 2014, , 32-40.		0
408	Drug-Induced Liver Injury. , 2014, , 23-31.		0
409	Approach to the Patient with Jaundice. , 2014, , 13-22.		0
410	HIV/HCV and HIV/HBV Co-infections. , 2014, , 78-95.		0
411	Alpha-1 Antitrypsin Deficiency. , 2014, , 187-195.		0
412	Live Donor Transplantation Evaluation. , 2014, , 415-420.		0
413	Evaluation of Patients for Liver Transplantation. , 2014, , 405-414.		0
414	Hepatopulmonary Syndrome. , 2014, , 255-262.		0

#	Article	IF	Citations
415	Portopulmonary Hypertension. , 2014, , 263-270.		0
416	Diagnosis and Management of Acute Liver Failure: A Pediatric Perspective. , 2014, , 351-364.		0
417	Budd-Chiari Syndrome. , 2014, , 294-300.		0
418	Portal Vein Thrombosis. , 2014, , 301-307.		0
419	Liver Lesions. , 2014, , 317-324.		0
420	Cystic Lesions of the Liver. , 2014, , 325-333.		0
421	Surgery in Patients with Liver Disease. , 2014, , 334-343.		0
422	Non-Alcoholic Fatty Liver Disease. , 2014, , 132-141.		0
423	Biliary Infections. , 2014, , 111-119.		0
424	Liver Transplantation: A Pediatric Perspective. , 2014, , 394-403.		0
425	Management of End-Stage Liver Disease in Children. , 2014, , 382-393.		0
426	Approach to Jaundice in Infancy. , 2014, , 374-381.		0
427	Liver Function Tests in Childhood. , 2014, , 365-373.		0
428	Surgical Evaluation for Liver Transplantation. , 2014, , 421-426.		0
429	Post-Operative Care of The Liver Transplantation Patient. , 2014, , 427-435.		0
430	Chronic Rejection. , 2014, , 453-461.		0
431	Ischemia Reperfusion Injury after Liver Transplantation. , 2014, , 469-476.		0
432	Vascular Complications of Liver Transplantation. , 2014, , 477-485.		0

#	Article	IF	Citations
433	Biliary Complications after Liver Transplantation. , 2014, , 486-493.		0
434	Approach to Prophylaxis and Management of Infections after Liver Transplantation. , 2014, , 494-503.		0
435	Malignancy after Liver Transplantation. , 2014, , 504-511.		0
436	Hepatitis C Post-Liver Transplantation. , 2014, , 512-520.		0
437	Recurrent Disease Post-Liver Transplantation: Autoimmune Diseases, Hepatitis B and NASH. , 2014, , 521-529.		0
438	Health Maintenance after Liver Transplantation. , 2014, , 530-537.		0
439	Approach to the Patient with Abnormal Liver Tests. , 2014, , 1-12.		0
440	Acute Rejection. , 2014, , 444-452.		0
441	Spontaneous Bacterial Peritonitis. , 2014, , 227-234.		0
442	Pregnancy-Related Liver Disease. , 2014, , 271-279.		0
443	Diagnostic Approach to Abnormal Liver Tests Following Liver Transplantation. , 2014, , 436-443.		0
444	Final and future frontiers. Journal of Hepatology, 2014, 61, 969-970.	1.8	0
445	Autoimmune Hepatitis and Overlap Syndromes. , 2014, , 142-150.		0
446	Hepatic Abscess. , 2014, , 96-110.		0
447	Non-Cirrhotic Portal Hypertension. , 2014, , 308-316.		0
448	Tracking HCC pathogenesis but not the tumor cells after biopsy. Journal of Hepatology, 2014, 61, 457-458.	1.8	0
449	The future of hepatology: Embrace change. Clinical Liver Disease, 2015, 5, 127-128.	1.0	0
450	Principles on the path to a hepatologist's enlightenment. Hepatology, 2015, 62, 8-12.	3.6	0

#	Article	IF	Citations
451	Reply. Hepatology, 2016, 64, 2266-2267.	3.6	0
452	A physician-scientistâ€™s wish list for the 2016 U.S. presidential candidates. Science Translational Medicine, 2016, 8, 351ed11.	5.8	0
453	Liver fibrogenesis. , 2017, , 110-122.e5.		0
454	Scientific Business Abstracts of the 112th Annual Meeting of the Association of Physicians of Great Britain and Ireland. QJM - Monthly Journal of the Association of Physicians, 2018, 111, 920-924.	0.2	0
455	Noninvasive point-of-care 13C-Methacetin Breath Test (MBT) predicts risk of clinical deterioration independently of currently used prognostic indicators in patients with decompensated NASH cirrhosis. Journal of Hepatology, 2020, 73, S139-S140.	1.8	0
456	Human Hepatic Stellate Cells Carry a New Splice Variant of the Human ADAMTS13. Blood, 2008, 112, 4085-4085.	0.6	0
457	Cell Death and Autophagy in Hepatic Stellate Cell Activation and Function. , 2017, , 39-52.		0
458	Title is missing!. , 2021, 16, e0244763.		0
459	Title is missing!. , 2021, 16, e0244763.		0
460	Title is missing!. , 2021, 16, e0244763.		0
461	Title is missing!. , 2021, 16, e0244763.		0